Bioelectric device developer NeoTherma Oncology is developing what is defined as a groundbreaking type of radio frequency (RF) thermal treament for deep, solid tumors. The device is expected to increase the effectiveness of current cancer treatments while also minimizing the harshest effects of chemotherapy and radiation. The firm's non-invasive technology is designed seamlessly to integrate into established MRI treatment suites, and clinical development strategy. Potentially relevant to a range of cancers, an initial focus of the firm is on Pancreatic Ductal Adenocarcinoma, the eighth most common cancer but the fourth leading cause of cancer death in the United States. For this application, the firm's device has already won a breakthrough therapy designation from the FDA.
